Biopharmaceutical Infrastructure Key to Lower Drug Development Costs (IMAGE)
Caption
A new NIST-sponsored study found that the biopharmaceutical industry spend a total of $1,219 million on infrastructure technology?884 million on the R&D technology infrastructure including bioimaging, biomarkers, informatics, and gene expression and $335 million on infrastructure for commercial manufacturing and postmarket surveillance.
Credit
NIST
Usage Restrictions
None
License
Licensed content